Drug Trial Radar · NCT05541016
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
455
Planned (sponsor's estimate)
Start
Mar 20, 2023
Primary completion
Sep 6, 2029
Study completion Sep 6, 2029
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial examines the use of blood-based biomarkers is to help inform decision making for treatment and radiation therapy for patients with human papillomavirus (HPV) positive oropharyngeal squamous cell cancers. The standard treatments for head and neck cancers are radiation therapy with chemotherapy or surgery potentially followed by radiation therapy with or without chemotherapy. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving chemotherapy along with radiation may kill more tumor cells. However, the cancer can recur or can spread to other parts of the body and all treatments can be associated with side effects. The purpose of this study is to evaluate a blood-based biomarker, using the NavDx testing device, for head and neck cancers in order to see if it can help improve selection of the intensity of treatment in order to best balance the side effects of treatment with the goal of decreasing cancer recurrence. This test could aid in early detection of recurrence and salvage therapy.
Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma
- Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo blood and saliva specimen collection for NavDx testing
CisplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT scan
Diffusing Alpha-emitter Radiation TherapyRadiation
Undergo DART
DocetaxelDrug
Given IV
Intensity-Modulated Proton TherapyProcedure
Undergo IMPT
Intensity-Modulated Radiation TherapyRadiation
Undergo IMRT
Magnetic Resonance ImagingProcedure
Undergo MRI
Modified Barium Swallow StudyProcedure
Undergo MBSS
Observation ActivityOther
Undergo observation
Positron Emission TomographyProcedure
Undergo PET scan
Quality-of-Life AssessmentOther
Ancillary studies
QuestionnaireOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: From registration to the first of either disease progression/recurrence or death, assessed up to 5 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.